nodes	percent_of_prediction	percent_of_DWPC	metapath
Paliperidone—CYP3A5—Temsirolimus—kidney cancer	0.0832	0.147	CbGbCtD
Paliperidone—HTR2C—Sorafenib—kidney cancer	0.0518	0.0915	CbGbCtD
Paliperidone—CYP2D6—Temsirolimus—kidney cancer	0.051	0.09	CbGbCtD
Paliperidone—CYP3A4—Everolimus—kidney cancer	0.048	0.0848	CbGbCtD
Paliperidone—CYP3A4—Temsirolimus—kidney cancer	0.0324	0.0572	CbGbCtD
Paliperidone—CYP3A5—Erlotinib—kidney cancer	0.0312	0.055	CbGbCtD
Paliperidone—CYP3A5—Paclitaxel—kidney cancer	0.0285	0.0504	CbGbCtD
Paliperidone—CYP2D6—Pazopanib—kidney cancer	0.0268	0.0473	CbGbCtD
Paliperidone—CYP3A5—Sorafenib—kidney cancer	0.0253	0.0447	CbGbCtD
Paliperidone—CYP3A5—Vincristine—kidney cancer	0.0246	0.0434	CbGbCtD
Paliperidone—CYP3A5—Sunitinib—kidney cancer	0.0205	0.0363	CbGbCtD
Paliperidone—CYP2D6—Erlotinib—kidney cancer	0.0191	0.0337	CbGbCtD
Paliperidone—CYP3A4—Pazopanib—kidney cancer	0.017	0.0301	CbGbCtD
Paliperidone—CYP2D6—Sorafenib—kidney cancer	0.0155	0.0274	CbGbCtD
Paliperidone—CYP2D6—Vinblastine—kidney cancer	0.0153	0.0271	CbGbCtD
Paliperidone—CYP3A4—Erlotinib—kidney cancer	0.0122	0.0215	CbGbCtD
Paliperidone—CYP3A4—Paclitaxel—kidney cancer	0.0111	0.0196	CbGbCtD
Paliperidone—CYP3A4—Sorafenib—kidney cancer	0.00988	0.0174	CbGbCtD
Paliperidone—CYP3A4—Vinblastine—kidney cancer	0.00976	0.0172	CbGbCtD
Paliperidone—CYP3A4—Vincristine—kidney cancer	0.00959	0.0169	CbGbCtD
Paliperidone—CYP2D6—Doxorubicin—kidney cancer	0.00943	0.0166	CbGbCtD
Paliperidone—CYP3A4—Sunitinib—kidney cancer	0.00801	0.0141	CbGbCtD
Paliperidone—CYP3A4—Doxorubicin—kidney cancer	0.006	0.0106	CbGbCtD
Paliperidone—HTR2A—urine—kidney cancer	0.00064	0.0928	CbGeAlD
Paliperidone—CYP3A4—urine—kidney cancer	0.000593	0.0859	CbGeAlD
Paliperidone—CYP2D6—urine—kidney cancer	0.000583	0.0846	CbGeAlD
Paliperidone—ADRA1B—renal system—kidney cancer	0.000431	0.0625	CbGeAlD
Paliperidone—ADRA1B—kidney—kidney cancer	0.000417	0.0604	CbGeAlD
Paliperidone—HTR1D—kidney—kidney cancer	0.000305	0.0442	CbGeAlD
Paliperidone—HTR1A—renal system—kidney cancer	0.000263	0.0381	CbGeAlD
Paliperidone—ADRA2C—nephron tubule—kidney cancer	0.000254	0.0368	CbGeAlD
Paliperidone—ADRA1A—renal system—kidney cancer	0.000242	0.0351	CbGeAlD
Paliperidone—ADRA2C—renal system—kidney cancer	0.000231	0.0335	CbGeAlD
Paliperidone—ADRA2C—kidney—kidney cancer	0.000223	0.0324	CbGeAlD
Paliperidone—ADRA2C—cortex of kidney—kidney cancer	0.000217	0.0315	CbGeAlD
Paliperidone—CYP3A5—nephron tubule—kidney cancer	0.000213	0.0308	CbGeAlD
Paliperidone—ADRA2C—cardiac atrium—kidney cancer	0.000207	0.03	CbGeAlD
Paliperidone—CYP3A5—renal system—kidney cancer	0.000193	0.028	CbGeAlD
Paliperidone—CYP3A5—kidney—kidney cancer	0.000187	0.0271	CbGeAlD
Paliperidone—CYP3A5—cortex of kidney—kidney cancer	0.000182	0.0264	CbGeAlD
Paliperidone—ADRA2A—cortex of kidney—kidney cancer	0.000174	0.0251	CbGeAlD
Paliperidone—ADRA2A—gonad—kidney cancer	0.000165	0.024	CbGeAlD
Paliperidone—ADRA2A—cardiac atrium—kidney cancer	0.000165	0.0239	CbGeAlD
Paliperidone—HTR2A—renal system—kidney cancer	0.000157	0.0227	CbGeAlD
Paliperidone—HTR2A—kidney—kidney cancer	0.000151	0.022	CbGeAlD
Paliperidone—CYP3A4—renal system—kidney cancer	0.000145	0.021	CbGeAlD
Paliperidone—CYP2D6—renal system—kidney cancer	0.000143	0.0207	CbGeAlD
Paliperidone—HTR2A—gonad—kidney cancer	0.000141	0.0204	CbGeAlD
Paliperidone—CYP3A4—kidney—kidney cancer	0.00014	0.0203	CbGeAlD
Paliperidone—CYP2D6—kidney—kidney cancer	0.000138	0.02	CbGeAlD
Paliperidone—Nausea—Erlotinib—kidney cancer	0.000115	0.000298	CcSEcCtD
Paliperidone—Alopecia—Capecitabine—kidney cancer	0.000115	0.000298	CcSEcCtD
Paliperidone—Dry mouth—Paclitaxel—kidney cancer	0.000115	0.000298	CcSEcCtD
Paliperidone—Diarrhoea—Sunitinib—kidney cancer	0.000115	0.000297	CcSEcCtD
Paliperidone—Mental disorder—Capecitabine—kidney cancer	0.000114	0.000296	CcSEcCtD
Paliperidone—Asthenia—Dactinomycin—kidney cancer	0.000114	0.000295	CcSEcCtD
Paliperidone—Confusional state—Paclitaxel—kidney cancer	0.000113	0.000294	CcSEcCtD
Paliperidone—Malnutrition—Capecitabine—kidney cancer	0.000113	0.000294	CcSEcCtD
Paliperidone—Erythema—Capecitabine—kidney cancer	0.000113	0.000294	CcSEcCtD
Paliperidone—Anaphylactic shock—Paclitaxel—kidney cancer	0.000112	0.000292	CcSEcCtD
Paliperidone—Oedema—Paclitaxel—kidney cancer	0.000112	0.000292	CcSEcCtD
Paliperidone—Abdominal pain—Vincristine—kidney cancer	0.000112	0.000291	CcSEcCtD
Paliperidone—Body temperature increased—Vincristine—kidney cancer	0.000112	0.000291	CcSEcCtD
Paliperidone—Infection—Paclitaxel—kidney cancer	0.000112	0.00029	CcSEcCtD
Paliperidone—Flatulence—Capecitabine—kidney cancer	0.000111	0.000289	CcSEcCtD
Paliperidone—Dry skin—Doxorubicin—kidney cancer	0.000111	0.000288	CcSEcCtD
Paliperidone—Dysgeusia—Capecitabine—kidney cancer	0.000111	0.000288	CcSEcCtD
Paliperidone—Dizziness—Sunitinib—kidney cancer	0.000111	0.000287	CcSEcCtD
Paliperidone—Feeling abnormal—Gemcitabine—kidney cancer	0.000111	0.000287	CcSEcCtD
Paliperidone—Shock—Paclitaxel—kidney cancer	0.000111	0.000287	CcSEcCtD
Paliperidone—Vomiting—Sorafenib—kidney cancer	0.000111	0.000287	CcSEcCtD
Paliperidone—Abdominal pain upper—Doxorubicin—kidney cancer	0.000111	0.000287	CcSEcCtD
Paliperidone—Orthostatic hypotension—Doxorubicin—kidney cancer	0.000111	0.000287	CcSEcCtD
Paliperidone—Nervous system disorder—Paclitaxel—kidney cancer	0.00011	0.000286	CcSEcCtD
Paliperidone—Thrombocytopenia—Paclitaxel—kidney cancer	0.00011	0.000286	CcSEcCtD
Paliperidone—Tachycardia—Paclitaxel—kidney cancer	0.00011	0.000285	CcSEcCtD
Paliperidone—Rash—Sorafenib—kidney cancer	0.00011	0.000285	CcSEcCtD
Paliperidone—Dermatitis—Sorafenib—kidney cancer	0.00011	0.000285	CcSEcCtD
Paliperidone—Back pain—Capecitabine—kidney cancer	0.000109	0.000284	CcSEcCtD
Paliperidone—Breast disorder—Doxorubicin—kidney cancer	0.000109	0.000284	CcSEcCtD
Paliperidone—Skin disorder—Paclitaxel—kidney cancer	0.000109	0.000284	CcSEcCtD
Paliperidone—Aspartate aminotransferase increased—Doxorubicin—kidney cancer	0.000109	0.000283	CcSEcCtD
Paliperidone—Headache—Sorafenib—kidney cancer	0.000109	0.000283	CcSEcCtD
Paliperidone—Muscle spasms—Capecitabine—kidney cancer	0.000109	0.000282	CcSEcCtD
Paliperidone—Diarrhoea—Dactinomycin—kidney cancer	0.000108	0.000282	CcSEcCtD
Paliperidone—Nasopharyngitis—Doxorubicin—kidney cancer	0.000108	0.000281	CcSEcCtD
Paliperidone—Anorexia—Paclitaxel—kidney cancer	0.000107	0.000278	CcSEcCtD
Paliperidone—Alanine aminotransferase increased—Doxorubicin—kidney cancer	0.000107	0.000277	CcSEcCtD
Paliperidone—Muscular weakness—Doxorubicin—kidney cancer	0.000107	0.000277	CcSEcCtD
Paliperidone—Vision blurred—Capecitabine—kidney cancer	0.000107	0.000277	CcSEcCtD
Paliperidone—Vomiting—Sunitinib—kidney cancer	0.000106	0.000276	CcSEcCtD
Paliperidone—Body temperature increased—Gemcitabine—kidney cancer	0.000106	0.000276	CcSEcCtD
Paliperidone—Tremor—Capecitabine—kidney cancer	0.000106	0.000275	CcSEcCtD
Paliperidone—Rash—Sunitinib—kidney cancer	0.000106	0.000274	CcSEcCtD
Paliperidone—Dermatitis—Sunitinib—kidney cancer	0.000105	0.000274	CcSEcCtD
Paliperidone—Hypotension—Paclitaxel—kidney cancer	0.000105	0.000273	CcSEcCtD
Paliperidone—Ill-defined disorder—Capecitabine—kidney cancer	0.000105	0.000272	CcSEcCtD
Paliperidone—Headache—Sunitinib—kidney cancer	0.000105	0.000272	CcSEcCtD
Paliperidone—Influenza—Doxorubicin—kidney cancer	0.000105	0.000272	CcSEcCtD
Paliperidone—Dysphagia—Doxorubicin—kidney cancer	0.000105	0.000272	CcSEcCtD
Paliperidone—Anaemia—Capecitabine—kidney cancer	0.000104	0.000271	CcSEcCtD
Paliperidone—Hypersensitivity—Vincristine—kidney cancer	0.000104	0.000271	CcSEcCtD
Paliperidone—Nausea—Sorafenib—kidney cancer	0.000103	0.000268	CcSEcCtD
Paliperidone—Pancreatitis—Doxorubicin—kidney cancer	0.000103	0.000266	CcSEcCtD
Paliperidone—Musculoskeletal discomfort—Paclitaxel—kidney cancer	0.000102	0.000266	CcSEcCtD
Paliperidone—Malaise—Capecitabine—kidney cancer	0.000102	0.000265	CcSEcCtD
Paliperidone—Insomnia—Paclitaxel—kidney cancer	0.000102	0.000264	CcSEcCtD
Paliperidone—Vertigo—Capecitabine—kidney cancer	0.000102	0.000264	CcSEcCtD
Paliperidone—Asthenia—Vincristine—kidney cancer	0.000102	0.000264	CcSEcCtD
Paliperidone—Syncope—Capecitabine—kidney cancer	0.000101	0.000263	CcSEcCtD
Paliperidone—Leukopenia—Capecitabine—kidney cancer	0.000101	0.000263	CcSEcCtD
Paliperidone—Paraesthesia—Paclitaxel—kidney cancer	0.000101	0.000262	CcSEcCtD
Paliperidone—Vomiting—Dactinomycin—kidney cancer	0.000101	0.000262	CcSEcCtD
Paliperidone—Bronchitis—Doxorubicin—kidney cancer	0.000101	0.000261	CcSEcCtD
Paliperidone—Dyspnoea—Paclitaxel—kidney cancer	0.0001	0.00026	CcSEcCtD
Paliperidone—Somnolence—Paclitaxel—kidney cancer	9.99e-05	0.00026	CcSEcCtD
Paliperidone—Palpitations—Capecitabine—kidney cancer	9.99e-05	0.00026	CcSEcCtD
Paliperidone—Rash—Dactinomycin—kidney cancer	9.99e-05	0.000259	CcSEcCtD
Paliperidone—Nausea—Sunitinib—kidney cancer	9.94e-05	0.000258	CcSEcCtD
Paliperidone—Loss of consciousness—Capecitabine—kidney cancer	9.94e-05	0.000258	CcSEcCtD
Paliperidone—Dyspepsia—Paclitaxel—kidney cancer	9.9e-05	0.000257	CcSEcCtD
Paliperidone—Cough—Capecitabine—kidney cancer	9.86e-05	0.000256	CcSEcCtD
Paliperidone—Neutropenia—Doxorubicin—kidney cancer	9.78e-05	0.000254	CcSEcCtD
Paliperidone—Dysuria—Doxorubicin—kidney cancer	9.78e-05	0.000254	CcSEcCtD
Paliperidone—Decreased appetite—Paclitaxel—kidney cancer	9.77e-05	0.000254	CcSEcCtD
Paliperidone—Hypertension—Capecitabine—kidney cancer	9.76e-05	0.000254	CcSEcCtD
Paliperidone—Upper respiratory tract infection—Doxorubicin—kidney cancer	9.72e-05	0.000252	CcSEcCtD
Paliperidone—Gastrointestinal disorder—Paclitaxel—kidney cancer	9.71e-05	0.000252	CcSEcCtD
Paliperidone—Fatigue—Paclitaxel—kidney cancer	9.69e-05	0.000252	CcSEcCtD
Paliperidone—Diarrhoea—Vincristine—kidney cancer	9.68e-05	0.000252	CcSEcCtD
Paliperidone—Pollakiuria—Doxorubicin—kidney cancer	9.66e-05	0.000251	CcSEcCtD
Paliperidone—Asthenia—Gemcitabine—kidney cancer	9.63e-05	0.00025	CcSEcCtD
Paliperidone—Arthralgia—Capecitabine—kidney cancer	9.62e-05	0.00025	CcSEcCtD
Paliperidone—Myalgia—Capecitabine—kidney cancer	9.62e-05	0.00025	CcSEcCtD
Paliperidone—Chest pain—Capecitabine—kidney cancer	9.62e-05	0.00025	CcSEcCtD
Paliperidone—Pain—Paclitaxel—kidney cancer	9.61e-05	0.00025	CcSEcCtD
Paliperidone—Constipation—Paclitaxel—kidney cancer	9.61e-05	0.00025	CcSEcCtD
Paliperidone—Anxiety—Capecitabine—kidney cancer	9.59e-05	0.000249	CcSEcCtD
Paliperidone—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—kidney cancer	9.56e-05	0.000248	CcSEcCtD
Paliperidone—Weight increased—Doxorubicin—kidney cancer	9.52e-05	0.000247	CcSEcCtD
Paliperidone—Discomfort—Capecitabine—kidney cancer	9.51e-05	0.000247	CcSEcCtD
Paliperidone—Pruritus—Gemcitabine—kidney cancer	9.5e-05	0.000247	CcSEcCtD
Paliperidone—Weight decreased—Doxorubicin—kidney cancer	9.46e-05	0.000246	CcSEcCtD
Paliperidone—Hyperglycaemia—Doxorubicin—kidney cancer	9.43e-05	0.000245	CcSEcCtD
Paliperidone—Dry mouth—Capecitabine—kidney cancer	9.41e-05	0.000245	CcSEcCtD
Paliperidone—Nausea—Dactinomycin—kidney cancer	9.41e-05	0.000244	CcSEcCtD
Paliperidone—Pneumonia—Doxorubicin—kidney cancer	9.38e-05	0.000244	CcSEcCtD
Paliperidone—Dizziness—Vincristine—kidney cancer	9.36e-05	0.000243	CcSEcCtD
Paliperidone—Infestation—Doxorubicin—kidney cancer	9.32e-05	0.000242	CcSEcCtD
Paliperidone—Infestation NOS—Doxorubicin—kidney cancer	9.32e-05	0.000242	CcSEcCtD
Paliperidone—Confusional state—Capecitabine—kidney cancer	9.3e-05	0.000242	CcSEcCtD
Paliperidone—Feeling abnormal—Paclitaxel—kidney cancer	9.26e-05	0.000241	CcSEcCtD
Paliperidone—Oedema—Capecitabine—kidney cancer	9.23e-05	0.00024	CcSEcCtD
Paliperidone—Gastrointestinal pain—Paclitaxel—kidney cancer	9.19e-05	0.000239	CcSEcCtD
Paliperidone—Diarrhoea—Gemcitabine—kidney cancer	9.19e-05	0.000239	CcSEcCtD
Paliperidone—Infection—Capecitabine—kidney cancer	9.17e-05	0.000238	CcSEcCtD
Paliperidone—Jaundice—Doxorubicin—kidney cancer	9.09e-05	0.000236	CcSEcCtD
Paliperidone—Shock—Capecitabine—kidney cancer	9.08e-05	0.000236	CcSEcCtD
Paliperidone—Conjunctivitis—Doxorubicin—kidney cancer	9.06e-05	0.000235	CcSEcCtD
Paliperidone—Urinary tract infection—Doxorubicin—kidney cancer	9.06e-05	0.000235	CcSEcCtD
Paliperidone—Nervous system disorder—Capecitabine—kidney cancer	9.05e-05	0.000235	CcSEcCtD
Paliperidone—Thrombocytopenia—Capecitabine—kidney cancer	9.03e-05	0.000235	CcSEcCtD
Paliperidone—Tachycardia—Capecitabine—kidney cancer	9e-05	0.000234	CcSEcCtD
Paliperidone—Vomiting—Vincristine—kidney cancer	9e-05	0.000234	CcSEcCtD
Paliperidone—Skin disorder—Capecitabine—kidney cancer	8.96e-05	0.000233	CcSEcCtD
Paliperidone—Urticaria—Paclitaxel—kidney cancer	8.93e-05	0.000232	CcSEcCtD
Paliperidone—Rash—Vincristine—kidney cancer	8.92e-05	0.000232	CcSEcCtD
Paliperidone—Dermatitis—Vincristine—kidney cancer	8.92e-05	0.000232	CcSEcCtD
Paliperidone—Abdominal pain—Paclitaxel—kidney cancer	8.89e-05	0.000231	CcSEcCtD
Paliperidone—Body temperature increased—Paclitaxel—kidney cancer	8.89e-05	0.000231	CcSEcCtD
Paliperidone—Headache—Vincristine—kidney cancer	8.87e-05	0.00023	CcSEcCtD
Paliperidone—Hepatobiliary disease—Doxorubicin—kidney cancer	8.82e-05	0.000229	CcSEcCtD
Paliperidone—Epistaxis—Doxorubicin—kidney cancer	8.8e-05	0.000228	CcSEcCtD
Paliperidone—Anorexia—Capecitabine—kidney cancer	8.79e-05	0.000228	CcSEcCtD
Paliperidone—Sinusitis—Doxorubicin—kidney cancer	8.75e-05	0.000227	CcSEcCtD
Paliperidone—Agranulocytosis—Doxorubicin—kidney cancer	8.7e-05	0.000226	CcSEcCtD
Paliperidone—Hypotension—Capecitabine—kidney cancer	8.62e-05	0.000224	CcSEcCtD
Paliperidone—Vomiting—Gemcitabine—kidney cancer	8.54e-05	0.000222	CcSEcCtD
Paliperidone—Bradycardia—Doxorubicin—kidney cancer	8.52e-05	0.000221	CcSEcCtD
Paliperidone—Rash—Gemcitabine—kidney cancer	8.47e-05	0.00022	CcSEcCtD
Paliperidone—Dermatitis—Gemcitabine—kidney cancer	8.46e-05	0.00022	CcSEcCtD
Paliperidone—Headache—Gemcitabine—kidney cancer	8.41e-05	0.000219	CcSEcCtD
Paliperidone—Nausea—Vincristine—kidney cancer	8.41e-05	0.000218	CcSEcCtD
Paliperidone—Musculoskeletal discomfort—Capecitabine—kidney cancer	8.41e-05	0.000218	CcSEcCtD
Paliperidone—Rhinitis—Doxorubicin—kidney cancer	8.39e-05	0.000218	CcSEcCtD
Paliperidone—Insomnia—Capecitabine—kidney cancer	8.34e-05	0.000217	CcSEcCtD
Paliperidone—Hypoaesthesia—Doxorubicin—kidney cancer	8.33e-05	0.000216	CcSEcCtD
Paliperidone—Paraesthesia—Capecitabine—kidney cancer	8.28e-05	0.000215	CcSEcCtD
Paliperidone—Hypersensitivity—Paclitaxel—kidney cancer	8.28e-05	0.000215	CcSEcCtD
Paliperidone—Urinary tract disorder—Doxorubicin—kidney cancer	8.27e-05	0.000215	CcSEcCtD
Paliperidone—Oedema peripheral—Doxorubicin—kidney cancer	8.25e-05	0.000214	CcSEcCtD
Paliperidone—Connective tissue disorder—Doxorubicin—kidney cancer	8.23e-05	0.000214	CcSEcCtD
Paliperidone—Dyspnoea—Capecitabine—kidney cancer	8.23e-05	0.000214	CcSEcCtD
Paliperidone—Urethral disorder—Doxorubicin—kidney cancer	8.21e-05	0.000213	CcSEcCtD
Paliperidone—Dyspepsia—Capecitabine—kidney cancer	8.12e-05	0.000211	CcSEcCtD
Paliperidone—Asthenia—Paclitaxel—kidney cancer	8.07e-05	0.00021	CcSEcCtD
Paliperidone—Decreased appetite—Capecitabine—kidney cancer	8.02e-05	0.000208	CcSEcCtD
Paliperidone—Nausea—Gemcitabine—kidney cancer	7.98e-05	0.000207	CcSEcCtD
Paliperidone—Gastrointestinal disorder—Capecitabine—kidney cancer	7.97e-05	0.000207	CcSEcCtD
Paliperidone—Fatigue—Capecitabine—kidney cancer	7.95e-05	0.000207	CcSEcCtD
Paliperidone—Pruritus—Paclitaxel—kidney cancer	7.95e-05	0.000207	CcSEcCtD
Paliperidone—Pain—Capecitabine—kidney cancer	7.89e-05	0.000205	CcSEcCtD
Paliperidone—Constipation—Capecitabine—kidney cancer	7.89e-05	0.000205	CcSEcCtD
Paliperidone—Eye disorder—Doxorubicin—kidney cancer	7.82e-05	0.000203	CcSEcCtD
Paliperidone—Tinnitus—Doxorubicin—kidney cancer	7.8e-05	0.000203	CcSEcCtD
Paliperidone—Flushing—Doxorubicin—kidney cancer	7.77e-05	0.000202	CcSEcCtD
Paliperidone—Cardiac disorder—Doxorubicin—kidney cancer	7.77e-05	0.000202	CcSEcCtD
Paliperidone—Diarrhoea—Paclitaxel—kidney cancer	7.69e-05	0.0002	CcSEcCtD
Paliperidone—Feeling abnormal—Capecitabine—kidney cancer	7.6e-05	0.000198	CcSEcCtD
Paliperidone—Angiopathy—Doxorubicin—kidney cancer	7.59e-05	0.000197	CcSEcCtD
Paliperidone—Immune system disorder—Doxorubicin—kidney cancer	7.56e-05	0.000196	CcSEcCtD
Paliperidone—Gastrointestinal pain—Capecitabine—kidney cancer	7.54e-05	0.000196	CcSEcCtD
Paliperidone—Mediastinal disorder—Doxorubicin—kidney cancer	7.54e-05	0.000196	CcSEcCtD
Paliperidone—Chills—Doxorubicin—kidney cancer	7.51e-05	0.000195	CcSEcCtD
Paliperidone—Dizziness—Paclitaxel—kidney cancer	7.43e-05	0.000193	CcSEcCtD
Paliperidone—Alopecia—Doxorubicin—kidney cancer	7.4e-05	0.000192	CcSEcCtD
Paliperidone—Mental disorder—Doxorubicin—kidney cancer	7.33e-05	0.000191	CcSEcCtD
Paliperidone—Urticaria—Capecitabine—kidney cancer	7.33e-05	0.00019	CcSEcCtD
Paliperidone—Abdominal pain—Capecitabine—kidney cancer	7.29e-05	0.000189	CcSEcCtD
Paliperidone—Body temperature increased—Capecitabine—kidney cancer	7.29e-05	0.000189	CcSEcCtD
Paliperidone—Erythema—Doxorubicin—kidney cancer	7.29e-05	0.000189	CcSEcCtD
Paliperidone—Malnutrition—Doxorubicin—kidney cancer	7.29e-05	0.000189	CcSEcCtD
Paliperidone—Flatulence—Doxorubicin—kidney cancer	7.18e-05	0.000187	CcSEcCtD
Paliperidone—Tension—Doxorubicin—kidney cancer	7.15e-05	0.000186	CcSEcCtD
Paliperidone—Vomiting—Paclitaxel—kidney cancer	7.15e-05	0.000186	CcSEcCtD
Paliperidone—Dysgeusia—Doxorubicin—kidney cancer	7.14e-05	0.000185	CcSEcCtD
Paliperidone—Rash—Paclitaxel—kidney cancer	7.09e-05	0.000184	CcSEcCtD
Paliperidone—Dermatitis—Paclitaxel—kidney cancer	7.08e-05	0.000184	CcSEcCtD
Paliperidone—Nervousness—Doxorubicin—kidney cancer	7.08e-05	0.000184	CcSEcCtD
Paliperidone—Back pain—Doxorubicin—kidney cancer	7.05e-05	0.000183	CcSEcCtD
Paliperidone—Headache—Paclitaxel—kidney cancer	7.04e-05	0.000183	CcSEcCtD
Paliperidone—Muscle spasms—Doxorubicin—kidney cancer	7.01e-05	0.000182	CcSEcCtD
Paliperidone—Vision blurred—Doxorubicin—kidney cancer	6.87e-05	0.000178	CcSEcCtD
Paliperidone—Hypersensitivity—Capecitabine—kidney cancer	6.8e-05	0.000177	CcSEcCtD
Paliperidone—Ill-defined disorder—Doxorubicin—kidney cancer	6.76e-05	0.000176	CcSEcCtD
Paliperidone—Anaemia—Doxorubicin—kidney cancer	6.73e-05	0.000175	CcSEcCtD
Paliperidone—Agitation—Doxorubicin—kidney cancer	6.7e-05	0.000174	CcSEcCtD
Paliperidone—Nausea—Paclitaxel—kidney cancer	6.68e-05	0.000173	CcSEcCtD
Paliperidone—Asthenia—Capecitabine—kidney cancer	6.62e-05	0.000172	CcSEcCtD
Paliperidone—Malaise—Doxorubicin—kidney cancer	6.57e-05	0.000171	CcSEcCtD
Paliperidone—Vertigo—Doxorubicin—kidney cancer	6.55e-05	0.00017	CcSEcCtD
Paliperidone—Syncope—Doxorubicin—kidney cancer	6.53e-05	0.00017	CcSEcCtD
Paliperidone—Pruritus—Capecitabine—kidney cancer	6.53e-05	0.00017	CcSEcCtD
Paliperidone—Leukopenia—Doxorubicin—kidney cancer	6.52e-05	0.000169	CcSEcCtD
Paliperidone—Palpitations—Doxorubicin—kidney cancer	6.44e-05	0.000167	CcSEcCtD
Paliperidone—Loss of consciousness—Doxorubicin—kidney cancer	6.4e-05	0.000166	CcSEcCtD
Paliperidone—Cough—Doxorubicin—kidney cancer	6.36e-05	0.000165	CcSEcCtD
Paliperidone—Convulsion—Doxorubicin—kidney cancer	6.31e-05	0.000164	CcSEcCtD
Paliperidone—Diarrhoea—Capecitabine—kidney cancer	6.31e-05	0.000164	CcSEcCtD
Paliperidone—Hypertension—Doxorubicin—kidney cancer	6.29e-05	0.000163	CcSEcCtD
Paliperidone—Chest pain—Doxorubicin—kidney cancer	6.2e-05	0.000161	CcSEcCtD
Paliperidone—Arthralgia—Doxorubicin—kidney cancer	6.2e-05	0.000161	CcSEcCtD
Paliperidone—Myalgia—Doxorubicin—kidney cancer	6.2e-05	0.000161	CcSEcCtD
Paliperidone—Anxiety—Doxorubicin—kidney cancer	6.18e-05	0.000161	CcSEcCtD
Paliperidone—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—kidney cancer	6.16e-05	0.00016	CcSEcCtD
Paliperidone—Discomfort—Doxorubicin—kidney cancer	6.13e-05	0.000159	CcSEcCtD
Paliperidone—Dizziness—Capecitabine—kidney cancer	6.1e-05	0.000158	CcSEcCtD
Paliperidone—Dry mouth—Doxorubicin—kidney cancer	6.07e-05	0.000158	CcSEcCtD
Paliperidone—Confusional state—Doxorubicin—kidney cancer	6e-05	0.000156	CcSEcCtD
Paliperidone—Oedema—Doxorubicin—kidney cancer	5.95e-05	0.000154	CcSEcCtD
Paliperidone—Anaphylactic shock—Doxorubicin—kidney cancer	5.95e-05	0.000154	CcSEcCtD
Paliperidone—Infection—Doxorubicin—kidney cancer	5.91e-05	0.000153	CcSEcCtD
Paliperidone—Vomiting—Capecitabine—kidney cancer	5.87e-05	0.000152	CcSEcCtD
Paliperidone—Shock—Doxorubicin—kidney cancer	5.85e-05	0.000152	CcSEcCtD
Paliperidone—Nervous system disorder—Doxorubicin—kidney cancer	5.83e-05	0.000152	CcSEcCtD
Paliperidone—Thrombocytopenia—Doxorubicin—kidney cancer	5.82e-05	0.000151	CcSEcCtD
Paliperidone—Rash—Capecitabine—kidney cancer	5.82e-05	0.000151	CcSEcCtD
Paliperidone—Dermatitis—Capecitabine—kidney cancer	5.81e-05	0.000151	CcSEcCtD
Paliperidone—Tachycardia—Doxorubicin—kidney cancer	5.8e-05	0.000151	CcSEcCtD
Paliperidone—Headache—Capecitabine—kidney cancer	5.78e-05	0.00015	CcSEcCtD
Paliperidone—Skin disorder—Doxorubicin—kidney cancer	5.78e-05	0.00015	CcSEcCtD
Paliperidone—Anorexia—Doxorubicin—kidney cancer	5.67e-05	0.000147	CcSEcCtD
Paliperidone—Hypotension—Doxorubicin—kidney cancer	5.56e-05	0.000144	CcSEcCtD
Paliperidone—Nausea—Capecitabine—kidney cancer	5.48e-05	0.000142	CcSEcCtD
Paliperidone—Musculoskeletal discomfort—Doxorubicin—kidney cancer	5.42e-05	0.000141	CcSEcCtD
Paliperidone—Insomnia—Doxorubicin—kidney cancer	5.38e-05	0.00014	CcSEcCtD
Paliperidone—Paraesthesia—Doxorubicin—kidney cancer	5.34e-05	0.000139	CcSEcCtD
Paliperidone—Dyspnoea—Doxorubicin—kidney cancer	5.3e-05	0.000138	CcSEcCtD
Paliperidone—Somnolence—Doxorubicin—kidney cancer	5.29e-05	0.000137	CcSEcCtD
Paliperidone—Dyspepsia—Doxorubicin—kidney cancer	5.23e-05	0.000136	CcSEcCtD
Paliperidone—Decreased appetite—Doxorubicin—kidney cancer	5.17e-05	0.000134	CcSEcCtD
Paliperidone—Gastrointestinal disorder—Doxorubicin—kidney cancer	5.13e-05	0.000133	CcSEcCtD
Paliperidone—Fatigue—Doxorubicin—kidney cancer	5.13e-05	0.000133	CcSEcCtD
Paliperidone—Constipation—Doxorubicin—kidney cancer	5.09e-05	0.000132	CcSEcCtD
Paliperidone—Pain—Doxorubicin—kidney cancer	5.09e-05	0.000132	CcSEcCtD
Paliperidone—Feeling abnormal—Doxorubicin—kidney cancer	4.9e-05	0.000127	CcSEcCtD
Paliperidone—Gastrointestinal pain—Doxorubicin—kidney cancer	4.86e-05	0.000126	CcSEcCtD
Paliperidone—Urticaria—Doxorubicin—kidney cancer	4.72e-05	0.000123	CcSEcCtD
Paliperidone—Abdominal pain—Doxorubicin—kidney cancer	4.7e-05	0.000122	CcSEcCtD
Paliperidone—Body temperature increased—Doxorubicin—kidney cancer	4.7e-05	0.000122	CcSEcCtD
Paliperidone—Hypersensitivity—Doxorubicin—kidney cancer	4.38e-05	0.000114	CcSEcCtD
Paliperidone—Asthenia—Doxorubicin—kidney cancer	4.27e-05	0.000111	CcSEcCtD
Paliperidone—Pruritus—Doxorubicin—kidney cancer	4.21e-05	0.000109	CcSEcCtD
Paliperidone—Diarrhoea—Doxorubicin—kidney cancer	4.07e-05	0.000106	CcSEcCtD
Paliperidone—Dizziness—Doxorubicin—kidney cancer	3.93e-05	0.000102	CcSEcCtD
Paliperidone—Vomiting—Doxorubicin—kidney cancer	3.78e-05	9.82e-05	CcSEcCtD
Paliperidone—Rash—Doxorubicin—kidney cancer	3.75e-05	9.74e-05	CcSEcCtD
Paliperidone—Dermatitis—Doxorubicin—kidney cancer	3.75e-05	9.73e-05	CcSEcCtD
Paliperidone—Headache—Doxorubicin—kidney cancer	3.73e-05	9.68e-05	CcSEcCtD
Paliperidone—Nausea—Doxorubicin—kidney cancer	3.53e-05	9.18e-05	CcSEcCtD
Paliperidone—HTR1B—Signaling Pathways—VEGFA—kidney cancer	4.74e-06	0.000114	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—RAF1—kidney cancer	4.74e-06	0.000114	CbGpPWpGaD
Paliperidone—CYP2D6—Metabolism—CYP1A1—kidney cancer	4.73e-06	0.000113	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—RELA—kidney cancer	4.72e-06	0.000113	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—RAF1—kidney cancer	4.72e-06	0.000113	CbGpPWpGaD
Paliperidone—DRD3—Signaling Pathways—CTNNB1—kidney cancer	4.71e-06	0.000113	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—PSMD7—kidney cancer	4.7e-06	0.000113	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—RELA—kidney cancer	4.7e-06	0.000113	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—ERBB2—kidney cancer	4.69e-06	0.000112	CbGpPWpGaD
Paliperidone—DRD4—Signaling Pathways—VEGFA—kidney cancer	4.67e-06	0.000112	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—ERBB2—kidney cancer	4.67e-06	0.000112	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling by GPCR—MAPK1—kidney cancer	4.66e-06	0.000112	CbGpPWpGaD
Paliperidone—DRD1—Signaling Pathways—PTEN—kidney cancer	4.65e-06	0.000111	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—MTOR—kidney cancer	4.63e-06	0.000111	CbGpPWpGaD
Paliperidone—ADRA2C—Metabolism—PTEN—kidney cancer	4.63e-06	0.000111	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling by GPCR—PIK3CA—kidney cancer	4.62e-06	0.000111	CbGpPWpGaD
Paliperidone—DRD2—GPCR downstream signaling—PIK3CA—kidney cancer	4.62e-06	0.000111	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—MTOR—kidney cancer	4.61e-06	0.00011	CbGpPWpGaD
Paliperidone—DRD3—Signaling Pathways—PTEN—kidney cancer	4.59e-06	0.00011	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—RAF1—kidney cancer	4.59e-06	0.00011	CbGpPWpGaD
Paliperidone—HTR1D—Signaling Pathways—MAPK3—kidney cancer	4.58e-06	0.00011	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—RELA—kidney cancer	4.57e-06	0.000109	CbGpPWpGaD
Paliperidone—DRD2—Signaling by GPCR—KRAS—kidney cancer	4.57e-06	0.000109	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling by GPCR—PIK3CA—kidney cancer	4.55e-06	0.000109	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling by GPCR—MAPK3—kidney cancer	4.55e-06	0.000109	CbGpPWpGaD
Paliperidone—HTR2A—GPCR downstream signaling—PIK3CA—kidney cancer	4.55e-06	0.000109	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—ERBB2—kidney cancer	4.54e-06	0.000109	CbGpPWpGaD
Paliperidone—HRH1—GPCR downstream signaling—PIK3CA—kidney cancer	4.54e-06	0.000109	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—POMC—kidney cancer	4.52e-06	0.000108	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—RAF1—kidney cancer	4.52e-06	0.000108	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—CDKN1B—kidney cancer	4.5e-06	0.000108	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—RELA—kidney cancer	4.5e-06	0.000108	CbGpPWpGaD
Paliperidone—HTR2A—Signaling by GPCR—KRAS—kidney cancer	4.49e-06	0.000108	CbGpPWpGaD
Paliperidone—HTR1B—Signaling Pathways—MAPK3—kidney cancer	4.49e-06	0.000108	CbGpPWpGaD
Paliperidone—HRH1—Signaling by GPCR—KRAS—kidney cancer	4.48e-06	0.000107	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—MTOR—kidney cancer	4.48e-06	0.000107	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—ERBB2—kidney cancer	4.47e-06	0.000107	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—BRAF—kidney cancer	4.46e-06	0.000107	CbGpPWpGaD
Paliperidone—HTR1D—Signaling Pathways—MYC—kidney cancer	4.46e-06	0.000107	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—BCHE—kidney cancer	4.46e-06	0.000107	CbGpPWpGaD
Paliperidone—ADRA1A—GPCR downstream signaling—PIK3CA—kidney cancer	4.45e-06	0.000107	CbGpPWpGaD
Paliperidone—DRD4—Signaling Pathways—MAPK3—kidney cancer	4.42e-06	0.000106	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—MTOR—kidney cancer	4.41e-06	0.000106	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—IL2—kidney cancer	4.4e-06	0.000106	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—SLC5A5—kidney cancer	4.4e-06	0.000105	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling by GPCR—KRAS—kidney cancer	4.4e-06	0.000105	CbGpPWpGaD
Paliperidone—HTR1B—Signaling Pathways—MYC—kidney cancer	4.36e-06	0.000105	CbGpPWpGaD
Paliperidone—HTR1D—Signaling Pathways—MAPK1—kidney cancer	4.36e-06	0.000104	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—CDKN1B—kidney cancer	4.35e-06	0.000104	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling by GPCR—MAPK1—kidney cancer	4.33e-06	0.000104	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—CDKN1B—kidney cancer	4.32e-06	0.000104	CbGpPWpGaD
Paliperidone—ADRA2A—Metabolism—PTGS2—kidney cancer	4.31e-06	0.000103	CbGpPWpGaD
Paliperidone—DRD4—Signaling Pathways—MYC—kidney cancer	4.3e-06	0.000103	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—CCND1—kidney cancer	4.29e-06	0.000103	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—JUN—kidney cancer	4.28e-06	0.000103	CbGpPWpGaD
Paliperidone—HTR1B—Signaling Pathways—MAPK1—kidney cancer	4.27e-06	0.000102	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—CTNNB1—kidney cancer	4.25e-06	0.000102	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—IL2—kidney cancer	4.25e-06	0.000102	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—SLC2A1—kidney cancer	4.25e-06	0.000102	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—IL2—kidney cancer	4.23e-06	0.000101	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—CDKN1B—kidney cancer	4.2e-06	0.000101	CbGpPWpGaD
Paliperidone—DRD1—Signaling Pathways—VEGFA—kidney cancer	4.2e-06	0.000101	CbGpPWpGaD
Paliperidone—DRD4—Signaling Pathways—MAPK1—kidney cancer	4.2e-06	0.000101	CbGpPWpGaD
Paliperidone—DRD2—Signaling by GPCR—PIK3CA—kidney cancer	4.2e-06	0.000101	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—RAF1—kidney cancer	4.16e-06	9.98e-05	CbGpPWpGaD
Paliperidone—DRD3—Signaling Pathways—VEGFA—kidney cancer	4.15e-06	9.94e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—RELA—kidney cancer	4.15e-06	9.93e-05	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—CCND1—kidney cancer	4.15e-06	9.93e-05	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—PTEN—kidney cancer	4.14e-06	9.93e-05	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—CDKN1B—kidney cancer	4.14e-06	9.92e-05	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—JUN—kidney cancer	4.14e-06	9.91e-05	CbGpPWpGaD
Paliperidone—ADRA2A—GPCR downstream signaling—PIK3CA—kidney cancer	4.14e-06	9.91e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling by GPCR—PIK3CA—kidney cancer	4.13e-06	9.89e-05	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—CCND1—kidney cancer	4.12e-06	9.88e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—ERBB2—kidney cancer	4.12e-06	9.87e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling by GPCR—PIK3CA—kidney cancer	4.12e-06	9.87e-05	CbGpPWpGaD
Paliperidone—HTR1D—Signaling Pathways—KRAS—kidney cancer	4.12e-06	9.87e-05	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—JUN—kidney cancer	4.12e-06	9.86e-05	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—IL2—kidney cancer	4.11e-06	9.86e-05	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—CTNNB1—kidney cancer	4.1e-06	9.84e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—RAF1—kidney cancer	4.1e-06	9.82e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—RAF1—kidney cancer	4.09e-06	9.8e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling by GPCR—KRAS—kidney cancer	4.09e-06	9.8e-05	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—CTNNB1—kidney cancer	4.08e-06	9.79e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—RELA—kidney cancer	4.08e-06	9.77e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—RELA—kidney cancer	4.07e-06	9.75e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—MTOR—kidney cancer	4.07e-06	9.74e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—ERBB2—kidney cancer	4.05e-06	9.71e-05	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—IL2—kidney cancer	4.05e-06	9.7e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—ERBB2—kidney cancer	4.04e-06	9.69e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling by GPCR—PIK3CA—kidney cancer	4.04e-06	9.69e-05	CbGpPWpGaD
Paliperidone—HTR1B—Signaling Pathways—KRAS—kidney cancer	4.03e-06	9.66e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—RAF1—kidney cancer	4.01e-06	9.61e-05	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—CCND1—kidney cancer	4.01e-06	9.61e-05	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—JUN—kidney cancer	4e-06	9.59e-05	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—PTEN—kidney cancer	4e-06	9.59e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—MTOR—kidney cancer	4e-06	9.59e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—RELA—kidney cancer	3.99e-06	9.57e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—MTOR—kidney cancer	3.99e-06	9.56e-05	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—PTEN—kidney cancer	3.98e-06	9.54e-05	CbGpPWpGaD
Paliperidone—DRD1—Signaling Pathways—MAPK3—kidney cancer	3.98e-06	9.53e-05	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—CTNNB1—kidney cancer	3.97e-06	9.52e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—ERBB2—kidney cancer	3.97e-06	9.51e-05	CbGpPWpGaD
Paliperidone—DRD4—Signaling Pathways—KRAS—kidney cancer	3.97e-06	9.51e-05	CbGpPWpGaD
Paliperidone—CYP3A5—Metabolism—PTGS2—kidney cancer	3.95e-06	9.47e-05	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—CCND1—kidney cancer	3.95e-06	9.46e-05	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—JUN—kidney cancer	3.94e-06	9.44e-05	CbGpPWpGaD
Paliperidone—DRD3—Signaling Pathways—MAPK3—kidney cancer	3.92e-06	9.4e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—MTOR—kidney cancer	3.92e-06	9.39e-05	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—CTNNB1—kidney cancer	3.91e-06	9.37e-05	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—PTEN—kidney cancer	3.87e-06	9.28e-05	CbGpPWpGaD
Paliperidone—DRD1—Signaling Pathways—MYC—kidney cancer	3.87e-06	9.27e-05	CbGpPWpGaD
Paliperidone—DRD3—Signaling Pathways—MYC—kidney cancer	3.82e-06	9.14e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—CDKN1B—kidney cancer	3.82e-06	9.14e-05	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—PTEN—kidney cancer	3.81e-06	9.13e-05	CbGpPWpGaD
Paliperidone—HTR1D—Signaling Pathways—PIK3CA—kidney cancer	3.78e-06	9.07e-05	CbGpPWpGaD
Paliperidone—DRD1—Signaling Pathways—MAPK1—kidney cancer	3.78e-06	9.06e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Metabolism—PTEN—kidney cancer	3.76e-06	9.01e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling by GPCR—PIK3CA—kidney cancer	3.76e-06	9e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—CDKN1B—kidney cancer	3.75e-06	9e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—CDKN1B—kidney cancer	3.75e-06	8.98e-05	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—VEGFA—kidney cancer	3.74e-06	8.97e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—IL2—kidney cancer	3.73e-06	8.95e-05	CbGpPWpGaD
Paliperidone—DRD3—Signaling Pathways—MAPK1—kidney cancer	3.73e-06	8.94e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—RAF1—kidney cancer	3.73e-06	8.93e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—RELA—kidney cancer	3.71e-06	8.89e-05	CbGpPWpGaD
Paliperidone—HTR1B—Signaling Pathways—PIK3CA—kidney cancer	3.71e-06	8.88e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—ERBB2—kidney cancer	3.69e-06	8.84e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—CDKN1B—kidney cancer	3.68e-06	8.81e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—IL2—kidney cancer	3.67e-06	8.8e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—IL2—kidney cancer	3.67e-06	8.78e-05	CbGpPWpGaD
Paliperidone—HTR1D—Signaling Pathways—TP53—kidney cancer	3.66e-06	8.77e-05	CbGpPWpGaD
Paliperidone—DRD4—Signaling Pathways—PIK3CA—kidney cancer	3.65e-06	8.74e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—CCND1—kidney cancer	3.64e-06	8.72e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—MTOR—kidney cancer	3.64e-06	8.72e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—JUN—kidney cancer	3.63e-06	8.7e-05	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—VEGFA—kidney cancer	3.61e-06	8.66e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—CTNNB1—kidney cancer	3.6e-06	8.64e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—IL2—kidney cancer	3.6e-06	8.62e-05	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—VEGFA—kidney cancer	3.6e-06	8.62e-05	CbGpPWpGaD
Paliperidone—HTR1B—Signaling Pathways—TP53—kidney cancer	3.58e-06	8.59e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—CCND1—kidney cancer	3.58e-06	8.58e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—JUN—kidney cancer	3.57e-06	8.56e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—CCND1—kidney cancer	3.57e-06	8.56e-05	CbGpPWpGaD
Paliperidone—DRD1—Signaling Pathways—KRAS—kidney cancer	3.57e-06	8.56e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—JUN—kidney cancer	3.57e-06	8.54e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—CTNNB1—kidney cancer	3.55e-06	8.5e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—GSTP1—kidney cancer	3.55e-06	8.5e-05	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—MAPK3—kidney cancer	3.54e-06	8.49e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—CTNNB1—kidney cancer	3.54e-06	8.48e-05	CbGpPWpGaD
Paliperidone—DRD4—Signaling Pathways—TP53—kidney cancer	3.53e-06	8.45e-05	CbGpPWpGaD
Paliperidone—DRD3—Signaling Pathways—KRAS—kidney cancer	3.53e-06	8.45e-05	CbGpPWpGaD
Paliperidone—CYP2D6—Metabolism—POMC—kidney cancer	3.52e-06	8.44e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—PTEN—kidney cancer	3.51e-06	8.42e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—CCND1—kidney cancer	3.51e-06	8.4e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—JUN—kidney cancer	3.5e-06	8.38e-05	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—VEGFA—kidney cancer	3.5e-06	8.38e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—CTNNB1—kidney cancer	3.47e-06	8.32e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—PTEN—kidney cancer	3.46e-06	8.28e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—PTEN—kidney cancer	3.45e-06	8.27e-05	CbGpPWpGaD
Paliperidone—CYP3A5—Metabolism—PTEN—kidney cancer	3.45e-06	8.26e-05	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—MYC—kidney cancer	3.44e-06	8.25e-05	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—VEGFA—kidney cancer	3.44e-06	8.25e-05	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—MAPK3—kidney cancer	3.42e-06	8.19e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—CDKN1B—kidney cancer	3.42e-06	8.18e-05	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—MAPK3—kidney cancer	3.4e-06	8.15e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—PTEN—kidney cancer	3.38e-06	8.11e-05	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—MAPK1—kidney cancer	3.37e-06	8.07e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—ABCB1—kidney cancer	3.36e-06	8.04e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—IL2—kidney cancer	3.34e-06	8.01e-05	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—MYC—kidney cancer	3.32e-06	7.97e-05	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—MAPK3—kidney cancer	3.31e-06	7.93e-05	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—MYC—kidney cancer	3.31e-06	7.93e-05	CbGpPWpGaD
Paliperidone—DRD1—Signaling Pathways—PIK3CA—kidney cancer	3.28e-06	7.87e-05	CbGpPWpGaD
Paliperidone—ADRA2C—Metabolism—PIK3CA—kidney cancer	3.27e-06	7.83e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—GSTM1—kidney cancer	3.26e-06	7.81e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—CCND1—kidney cancer	3.26e-06	7.81e-05	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—MAPK3—kidney cancer	3.26e-06	7.8e-05	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—MAPK1—kidney cancer	3.25e-06	7.79e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—JUN—kidney cancer	3.25e-06	7.79e-05	CbGpPWpGaD
Paliperidone—DRD3—Signaling Pathways—PIK3CA—kidney cancer	3.24e-06	7.76e-05	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—MAPK1—kidney cancer	3.24e-06	7.75e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—CTNNB1—kidney cancer	3.23e-06	7.73e-05	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—MYC—kidney cancer	3.22e-06	7.71e-05	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—KRAS—kidney cancer	3.18e-06	7.63e-05	CbGpPWpGaD
Paliperidone—DRD1—Signaling Pathways—TP53—kidney cancer	3.18e-06	7.61e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—VEGFA—kidney cancer	3.17e-06	7.6e-05	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—MYC—kidney cancer	3.17e-06	7.59e-05	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—MAPK1—kidney cancer	3.15e-06	7.54e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—PTEN—kidney cancer	3.14e-06	7.54e-05	CbGpPWpGaD
Paliperidone—DRD3—Signaling Pathways—TP53—kidney cancer	3.13e-06	7.51e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—VEGFA—kidney cancer	3.12e-06	7.48e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—VEGFA—kidney cancer	3.12e-06	7.47e-05	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—MAPK1—kidney cancer	3.1e-06	7.42e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—CYP1A1—kidney cancer	3.09e-06	7.4e-05	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—KRAS—kidney cancer	3.07e-06	7.36e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—VEGFA—kidney cancer	3.06e-06	7.33e-05	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—KRAS—kidney cancer	3.06e-06	7.32e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—MAPK3—kidney cancer	3e-06	7.19e-05	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—KRAS—kidney cancer	2.97e-06	7.12e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—MAPK3—kidney cancer	2.95e-06	7.08e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—MAPK3—kidney cancer	2.95e-06	7.06e-05	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—KRAS—kidney cancer	2.93e-06	7.01e-05	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—PIK3CA—kidney cancer	2.92e-06	7.01e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—MYC—kidney cancer	2.92e-06	7e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—MAPK3—kidney cancer	2.89e-06	6.93e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—MYC—kidney cancer	2.87e-06	6.88e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—MYC—kidney cancer	2.87e-06	6.87e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—MAPK1—kidney cancer	2.86e-06	6.84e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—VEGFA—kidney cancer	2.84e-06	6.81e-05	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—TP53—kidney cancer	2.83e-06	6.78e-05	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—PIK3CA—kidney cancer	2.82e-06	6.76e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—MYC—kidney cancer	2.81e-06	6.74e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—MAPK1—kidney cancer	2.81e-06	6.73e-05	CbGpPWpGaD
Paliperidone—CYP2D6—Metabolism—PTGS2—kidney cancer	2.81e-06	6.73e-05	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—PIK3CA—kidney cancer	2.81e-06	6.73e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—MAPK1—kidney cancer	2.8e-06	6.72e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—MAPK1—kidney cancer	2.75e-06	6.59e-05	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—PIK3CA—kidney cancer	2.73e-06	6.54e-05	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—TP53—kidney cancer	2.73e-06	6.54e-05	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—TP53—kidney cancer	2.72e-06	6.51e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—KRAS—kidney cancer	2.7e-06	6.46e-05	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—PIK3CA—kidney cancer	2.69e-06	6.44e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—MAPK3—kidney cancer	2.69e-06	6.44e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—KRAS—kidney cancer	2.65e-06	6.36e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Metabolism—PIK3CA—kidney cancer	2.65e-06	6.36e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—KRAS—kidney cancer	2.65e-06	6.35e-05	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—TP53—kidney cancer	2.64e-06	6.33e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—MYC—kidney cancer	2.61e-06	6.26e-05	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—TP53—kidney cancer	2.6e-06	6.23e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—KRAS—kidney cancer	2.6e-06	6.23e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—MAPK1—kidney cancer	2.56e-06	6.13e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—PIK3CA—kidney cancer	2.48e-06	5.94e-05	CbGpPWpGaD
Paliperidone—CYP2D6—Metabolism—PTEN—kidney cancer	2.45e-06	5.87e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—PIK3CA—kidney cancer	2.44e-06	5.84e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—PIK3CA—kidney cancer	2.43e-06	5.83e-05	CbGpPWpGaD
Paliperidone—CYP3A5—Metabolism—PIK3CA—kidney cancer	2.43e-06	5.83e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—KRAS—kidney cancer	2.41e-06	5.79e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—TP53—kidney cancer	2.4e-06	5.75e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—PIK3CA—kidney cancer	2.39e-06	5.72e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—TP53—kidney cancer	2.36e-06	5.65e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—TP53—kidney cancer	2.35e-06	5.64e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—TP53—kidney cancer	2.31e-06	5.54e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—POMC—kidney cancer	2.3e-06	5.52e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—PIK3CA—kidney cancer	2.22e-06	5.32e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—TP53—kidney cancer	2.15e-06	5.14e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—PTGS2—kidney cancer	1.84e-06	4.4e-05	CbGpPWpGaD
Paliperidone—CYP2D6—Metabolism—PIK3CA—kidney cancer	1.73e-06	4.14e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—PTEN—kidney cancer	1.6e-06	3.84e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—PIK3CA—kidney cancer	1.13e-06	2.71e-05	CbGpPWpGaD
